Pyridine cas no:110-86-1

NamePyridine
CAS110-86-1
SynonymsPyridine anhydrous; Azabenzene; Pyridin; Pyr
EINECS(EC#)203-809-9
Molecular FormulaC5H5N
Molecular Weight79.1

AppearanceClear clean liquid with characteristic odour
refractive index1.5085-1.5105
storage tempStore at RT.

Hazardclass3

Hazard F:Flammable;Xn:Harmful;
Risk R11;R20/21/22
Safety

Hazard Codes of Pyridine (CAS NO.110-86-1): T,N,F,Xn
Risk Statements: 11-20/21/22-39-23/24/25 
R11:Highly flammable. 
R20/21/22: Harmful by inhalation, in contact with skin and if swallowed. 
R39: Danger of very serious irreversible effects. 
R23/24/25: Toxic by inhalation, in contact with skin and if swallowed.
Safety Statements: 36/37/39-38-45-61-26-28-24/25-22-16-7 
S36/37/39: Wear suitable protective clothing, gloves and eye/face protection. 
S38: In case of insufficient ventilation, wear suitable respiratory equipment. 
S45: In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) 
S61: Avoid release to the environment. Refer to special instructions / safety data sheets. 
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. 
S28: After contact with skin, wash immediately with plenty of soap-suds. 
S24/25: Avoid contact with skin and eyes. 
S22: Do not breathe dust. 
S16: Keep away from sources of ignition. 
S7: Keep container tightly closed.
RIDADR :UN 1282 3/PG 2
WGK Germany: 2
RTECS: UR8400000
F: 3-10
Hazard Note: Highly Flammable/Harmful
HazardClass: 3
PackingGroup: II
Irritates skin and eye. Can cause dizziness, headache, central nervous system depression, gastrointestinal upset, and liver and kidney damage. 
Severe explosion hazard in the form of vapor when exposed to flame or spark. 
When heated to decomposition it emits highly toxic fumes of NOx.
Currently, there is inadequate evidence that it's a possible carcinogenic agent  in humans, though there is limited evidence of carcinogenic effects on animals.

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	intravenous	880mg/kg (880mg/kg)	CARDIAC: CHANGE IN RATE VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Toxicology. Vol. 4, Pg. 165, 1975.
frog	LDLo	parenteral	870mg/kg (870mg/kg)		"Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 695, 1948.
guinea pig	LD50	skin	1gm/kg (1000mg/kg)		"Prehled Prumyslove Toxikologie; Organicke Latky," Marhold, J., Prague, Czechoslovakia, Avicenum, 1986Vol. -, Pg. 839, 1986.
guinea pig	LDLo	intraperitoneal	870mg/kg (870mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Journal of Physiology. Vol. 17, Pg. 272, 1894.
guinea pig	LDLo	oral	4gm/kg (4000mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Journal of Physiology. Vol. 17, Pg. 272, 1894.
mammal (species unspecified)	LC50	inhalation	10gm/m3 (10000mg/m3)		Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. Vol. 32(10), Pg. 25, 1988.
mammal (species unspecified)	LD50	oral	1500mg/kg (1500mg/kg)		Gigiena Truda i Professional'nye Zabolevaniya. Labor Hygiene and Occupational Diseases. Vol. 32(10), Pg. 25, 1988.
mouse	LD50	intraperitoneal	950mg/kg (950mg/kg)		Progress in Biochemical Pharmacology. Vol. 1, Pg. 542, 1965.
mouse	LD50	intravenous	420mg/kg (420mg/kg)	BEHAVIORAL: SLEEP LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Pharmacological Research Communications. Vol. 5, Pg. 341, 1973.
mouse	LD50	oral	1500mg/kg (1500mg/kg)	BEHAVIORAL: SLEEP BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Pharmacological Research Communications. Vol. 5, Pg. 341, 1973.
mouse	LD50	subcutaneous	1250mg/kg (1250mg/kg)	BEHAVIORAL: SLEEP LUNGS, THORAX, OR RESPIRATION: DYSPNEA BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Pharmacological Research Communications. Vol. 5, Pg. 341, 1973.
rabbit	LD50	skin	1121mg/kg (1121mg/kg)	BEHAVIORAL: ATAXIA LIVER: OTHER CHANGES GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS	BIOFAX Industrial Bio-Test Laboratories, Inc., Data Sheets. Vol. 14-4/1970,
rabbit	LDLo	intraperitoneal	15mg/kg (15mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) BEHAVIORAL: GENERAL ANESTHETIC	Journal of Infectious Diseases. Vol. 42, Pg. 473, 1928.
rabbit	LDLo	subcutaneous	800mg/kg (800mg/kg)		"Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 695, 1948.
rat	LC50	inhalation	28500mg/m3/1H (28500mg/m3)	SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA	BIOFAX Industrial Bio-Test Laboratories, Inc., Data Sheets. Vol. 14-4/1970,
rat	LD50	intraperitoneal	866mg/kg (866mg/kg)		National Technical Information Service. Vol. PB195-158,
rat	LD50	intravenous	360mg/kg (360mg/kg)	BEHAVIORAL: SLEEP BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Pharmacological Research Communications. Vol. 5, Pg. 341, 1973.
rat	LD50	oral	891mg/kg (891mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: COMA	BIOFAX Industrial Bio-Test Laboratories, Inc., Data Sheets. Vol. 14-4/1970,
rat	LD50	subcutaneous	866mg/kg (866mg/kg)		Clinical Toxicology. Vol. 4, Pg. 185, 1971.